
Immuron hit with 44% first strike vote
Key points
- Immuron has received a first strike, with 43.58% of votes cast against its 2026 remuneration report.
- Shareholders also rejected an incentive plan renewal and a bid for more placement capacity.
- Immuron faces a possible board spill vote if its remuneration report draws another strike at next year’s AGM.
Immuron (ASX:IMC) received a first strike at its AGM, with 43.58% of votes cast against its 2026 remuneration report.
The vote came after the CEO’s AGM presentation showed FY27 sales to October up 10% to A$3.0 million, although US sales fell 19%.
Shareholders also rejected the renewal of Immuron’s Omnibus Incentive Plan, with 50.99% of votes against.
A special resolution to increase the company’s placement capacity failed with 65.62% support, short of the 75% it needed.
A second strike at next year’s AGM would trigger a vote on whether to spill the board.
Following the announcement the Immuron share price was unchanged at $0.037.
Shareholders re-elected director Dr Jeannette Joughin with 33.83% of votes against, and rejected Param Lally, a candidate the board did not endorse, with 70.33% against.
Immuron is a biopharmaceutical company whose main product, Travelan, aims to reduce the risk of travellers’ diarrhoea and is sold in Australia, the US and Canada.
Frequently asked questions
More from Australia
Northern Star’s new CEO says performance has fallen short
ASX finds Austral breached rules on A$6.9m deals
Tasmea’s second FY27 guidance upgrade points to 80% earnings growth
MinRes scraps executive exit pay vote as investor support falls short
Woolworths unveils $10b sales growth plan to investors
Anson Resources promotes Chris Moller to CFO


